Clinical trials: Nicotinamide
NAD+ Metabolism, Pharmacokinetics
Effects of Trigonelline Monohydrate on NAD+ Metabolism, Pharmacokinetics, Safety, and Tolerability in Healthy Adults
This Phase 1 study is designed to evaluate the pharmacokinetic, pharmacodynamic, bioavailability, safety, and tolerability effects of trigonelline monohydrate in generally healthy adults aged 40 to 70 years.
- Conditions
- NAD+ Metabolism, Pharmacokinetics, Bioavailability, Healthy Adults
- Trial name
- NCT07880925
- Testing
- Nicotinamide Mononucleotide (NMN), Trigonelline Monohydrate
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- dsm-firmenich Switzerland AG
Pain
Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy
The purpose of this study is to determine whether oxycodone HCl and niacin are effective in the treatment of pain following bunionectomy surgery.
- Trial name
- NCT00654069
- Testing
- Acurox 5/30 mg, Acurox 7.5/30
- Volunteers
- 405 people
- Sponsor
- Acura Pharmaceuticals Inc.
Dyslipidemia
Evaluation of a Flushing ASsessment Tool (FAST) in Subjects Receiving Niacin Extended-release Plus Aspirin
The primary purpose of this study was to evaluate the psychometric characteristics (reliability, validity, and responsiveness) of a Flushing ASsessment Tool (FAST) in subjects receiving niacin extended-release (NER) plus aspirin…
- Trial name
- NCT00630877
- Testing
- Niacin extended-release (NER), Aspirin (ASA)
- Where
- 40 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Neuralgia, Myalgia
Safety and Efficacy of Cunermuspir on Energy, Strength, and Fatigue in Patients With Nerve or Muscle Pain
Male and female participants were selected based on chronic neuromuscular pain. Patients were instructed to take two doses of the placebo or cuprous nicotinic acid chelate Cunermusmir twice a day for 28 days.
- Trial name
- NCT04737278
- Testing
- Cunermuspir
- Where
- Canada
- Volunteers
- 56 people
- Sponsor
- Mitosynergy LLC
Cardiovascular Diseases, Heart Diseases
Niacin Plus Statin to Prevent Vascular Events
The purpose of this study is to determine whether raising "good cholesterol" with a drug based on the vitamin niacin, while lowering "bad cholesterol" with a statin drug, can prevent more heart disease than the statin alone.
- Conditions
- Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease
- Trial name
- NCT00120289
- Testing
- Extended release niacin, Simvastatin
- Where
- 91 sites in United States, Canada
- Volunteers
- 3,414 people
- Sponsor
- Axio Research. LLC
Diabetes Mellitus Type 2
Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)
A study to assess the efficacy and tolerability of ER (Extended Release) niacin/laropiprant versus placebo in Type 2 Diabetes Mellitus patients.
- Trial name
- NCT00485758
- Testing
- ER niacin/laropiprant
- Volunteers
- 796 people
- Sponsor
- Merck Sharp & Dohme LLC
Acne, Post-inflammatory Hyperpigmentation
Clinical Efficacy of the Product in the Management of Facial Post Inflammatory Hyperpigmentation (PIHP) Subjects
Double-blind, randomized, clinical study is designed to evaluate the efficacy of Niacinamide A in the management of facial Post Inflammatory Hyper Pigmentation (PIHP) in healthy female and male subjects with moderate to severe…
- Trial name
- NCT06822335
- Where
- Mauritius
- Volunteers
- 65 people
- Sponsor
- Cosmetique Active International
Opioid Abuse
Study of the Abuse Liability of Oxycodone HCl/Niacin in Subjects With a History of Opioid Abuse
The purpose of this study is to assess the abuse liability of 4 times (8 tablets) the usual recommended dose of Acurox (oxycodone HCl 40 mg plus niacin 240 mg) versus oxycodone HCL 40 mg alone in subjects with a history of opioid…
- Trial name
- NCT00699010
- Testing
- Acurox 5/30mg taken first, Oxycodone 5mg taken first
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Acura Pharmaceuticals Inc.
Type 2 Diabetes Mellitus
A Study to Evaluate the Effects of ER Niacin/Laropiprant, Laropiprant, ER Niacin, and Placebo on Urinary Prostanoid Metabolites (0524A-079)(COMPLETED)
The purpose of this study is to evaluate the potential effects of ER niacin/laropiprant, ER niacin, laropiprant, and placebo over the course of seven days on urinary levels of a specific metabolite (which is a marker of in vivo…
- Trial name
- NCT00618995
- Testing
- Comparator: ER niacin (+) laropiprant, Comparator: ER niacin, Comparator: laropiprant
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Hyperlipidemia
Assessment of Interaction Between Vytorin and Niaspan in Healthy Subjects (P04955AM2)
This is a single-center, randomized, open-label, 3-period, 3-treatment multiple-dose crossover study designed to assess the interaction between VYTORIN® (Ezetimibe and Simvastatin) and NIASPAN® (Niacin Extended-Release Tablets)…
- Trial name
- NCT00652431
- Testing
- Vytorin + Niaspan, Vytorin, Niaspan
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Organon and Co
Hyperlipidemia, Mixed Dyslipidemia
An Open-Label Study to Compare the Lipid Effects of Niacin ER and Simvastatin (NS) to Atorvastatin in Subjects With Hyperlipidemia or Mixed Dyslipidemia (SUPREME)
To demonstrate that niacin ER and simvastatin (NS) tablets, when compared to atorvastatin (Lipitor®; Pfizer, Inc.), has superior high-density lipoprotein cholesterol (HDL-C) elevating effects at Week 12 in subjects with type II…
- Trial name
- SUPREME (NCT00465088)
- Testing
- Niacin ER/Simvastatin Tablets, atorvastatin
- Where
- 46 sites in United States
- Volunteers
- 199 people
- Sponsor
- Abbott
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Primary Hypercholesterolemia, Dyslipidemia
A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)
This study is being done to find out if tablets containing extended release (ER) niacin, laropiprant, and simvastatin (ERN/LRPT/SIM) are as effective as tablets containing ER niacin and laropiprant taken with simvastatin tablets…
- Trial name
- NCT01294683
- Testing
- Simvastatin, Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM), Extended Release (ER) niacin/laropiprant (N/LRPT)
- Volunteers
- 977 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertriglyceridemia
Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL
The primary objective is to determine the efficacy of AMR101 (ethyl icosapentate) compared to placebo in lowering fasting triglyceride levels in patients with very high fasting triglyceride levels ≥ 500 and ≤ 2000 mg/dL.
- Trial name
- MARINE (NCT01047683)
- Testing
- AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day
- Where
- 60 sites in United States, Denmark and 9 more
- Volunteers
- 229 people
- Sponsor
- Amarin Pharma Inc.
Healthy Volunteers
Safety and Pharmacokinetics of Nicotinamide Mononucleotide (NMN) in Healthy Adults.
The purpose of this study is to investigate the safety, pharmacokinetic profile, and effects of nicotinamide mononucleotide (NMN-C) in healthy adults, 18-65 years of age.
- Trial name
- NCT04910061
- Testing
- Nicotinamide mononucleotide (NMN-C)
- Where
- Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Seneque SA
Cognitive Function, Mood
A Study by ChromaDex to Assess the Effects of TRU NIAGEN on Cognitive Function, Mood and Sleep in Older Adults
The sponsor of this study is ChromaDex, Inc. This is a double-blind, randomized, crossover study to investigate the effects of 300 mg/d and 1000 mg/d TRU NIAGEN (nicotinamide riboside) compared to a placebo control on cognitive…
- Conditions
- Cognitive Function, Mood, Sleep
- Trial name
- NCT03562468
- Testing
- 300 mg/day of TRU NIAGEN (nicotinamide riboside), 1000 mg/day of TRU NIAGEN (nicotinamide riboside)
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- ChromaDex, Inc.
Carotid Atherosclerosis
Merck Carotid Atherosclerosis Trial (MK-0000-111)(COMPLETED)
This study will examine the effect of statin and niacin therapy on carotid plaque biomarkers
- Trial name
- MCAT (NCT00804843)
- Testing
- Atorvastatin/niacin extended-release, Atorvastatin, Simvastatin
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC
Enhance Immune Function
The Exploratory Study on the Nicotinamide Mononucleotide (Vital NAD ) to Promote the Rejuvenation of the Peripheral Blood Immune Cells of Adults.
The purpose of this study is to investigate the changes in adult peripheral blood immune cell subpopulations, subpopulations, and cell functional status before and after intervention with Nicotinamide Mononucleotide (Vital NAD )…
- Trial name
- NCT05984550
- Testing
- NMN
- Where
- China
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Shanghai Cell Therapy Group Co.,Ltd
Intermittent Claudication, Peripheral Vascular Disease
The Dose Response of Niacin ER/Lovastatin on Peak Walking Time (PWT) in Patients With Intermittent Claudication - TROPIC
The purpose of this study is to compare the dose response and safety of Niacin ER/Lovastatin, Niaspan® and Lovastatin with each other, in subjects with leg pain caused by a narrowing of their leg arteries.
- Trial name
- NCT00071266
- Testing
- Niacin Extended Release and Lovastatin Tablets
- Where
- 26 sites in United States
- Volunteers
- 870 people
- Sponsor
- Kos Pharmaceuticals
Intermittent Claudication, Peripheral Vascular Disease
Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication
The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg.
- Trial name
- NCT00062556
- Testing
- Niacin Extended Release and Lovastatin Tablets
- Volunteers
- 366 people
- Sponsor
- Kos Pharmaceuticals